文献速递眼底病与葡萄膜炎

抗VEGF药物治疗新生血管性年龄相关性黄斑变性的成本-效用分析

Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2020-06-19

该成本-效用分析比较贝伐珠单抗、雷珠单抗和阿柏西普单药治疗新生血管性年龄相关性黄斑变性(NVAMD)的11年和2年成本-效用。从眼科成本角度看,11年时三种药物均具成本效益,贝伐珠单抗成本效益分别是雷珠单抗的6.21倍和阿柏西普的3.06倍;2年时仅贝伐珠单抗具成本效益。早期治疗对获得最佳视力和成本效益至关重要。

要点

  • 11年时贝伐珠单抗、雷珠单抗和阿柏西普均具成本效益,贝伐珠单抗最优。
  • 2年时仅贝伐珠单抗具成本效益,雷珠单抗和阿柏西普不具成本效益。
  • 早期治疗的成本效益比晚期治疗高138%-149%。

核心结论

  • 从眼科成本角度看,三种抗VEGF药物单药治疗NVAMD在11年时均具成本效益,贝伐珠单抗成本效益最高。
  • 2年建模显示贝伐珠单抗具成本效益,而雷珠单抗和阿柏西普不具成本效益。
  • 早期治疗对获得最佳视力和成本效益至关重要,长期随访和治疗依从性也很重要。

研究设计与样本

  • 成本-效用分析,采用11年和2年眼科及社会成本视角,比较贝伐珠单抗、雷珠单抗和阿柏西普单药治疗NVAMD。
  • 使用患者效用值、双侧结局、2018年美元、视力相关死亡率、Medicare收费表以及CATT和VIEW试验数据,并参考Cochrane数据。
  • 研究设置于Center for Value-Based Medicine,患者人群为NVAMD患者,基于已发表数据进行成本-效用分析,将数据建模的10年视力结局向前模拟至第11年。

主要发现

  • 贝伐珠单抗和雷珠单抗在11年时各获得1.339 QALY增益,阿柏西普获得1.380 QALY增益(与观察相比)。
  • 阿柏西普相比雷珠单抗以更低成本获得更大QALY增益,但与贝伐珠单抗相比不具成本效益(增量成本-效用比$1,151,451/QALY)。
  • 11年时贝伐珠单抗、雷珠单抗和阿柏西普的平均眼科成本视角成本-效用比分别为$11,033/QALY、$79,600/QALY和$44,801/QALY。
  • 11年治疗挽回了11.0年预期寿命中因未治疗而损失的1.0年生命,早期治疗的成本效益比晚期治疗高138%-149%。
  • 2年治疗防止了1个月生命损失,贝伐珠单抗、雷珠单抗和阿柏西普分别获得0.141、0.141和0.164 QALY增益,相应平均成本-效用比分别为$40,371/QALY、$335,726/QALY和$168,006/QALY。

关键数值与推荐

  • $100,00/QALY被视为美国成本效益上限。
  • 11年时贝伐珠单抗成本效益是雷珠单抗的6.21倍,是阿柏西普的3.06倍。
  • 11年时贝伐珠单抗、雷珠单抗和阿柏西普的平均眼科成本视角成本-效用比分别为$11,033/QALY、$79,600/QALY和$44,801/QALY。
  • 2年时贝伐珠单抗、雷珠单抗和阿柏西普的平均成本-效用比分别为$40,371/QALY、$335,726/QALY和$168,006/QALY。

临床怎么用

  • 临床决策中可参考成本-效用数据选择抗VEGF药物,贝伐珠单抗在11年和2年时均具成本效益。
  • 应强调早期治疗以获取最佳视力和成本效益。
  • 长期随访和治疗依从性对维持视力获益和成本效益至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform 11- and 2-year health care sector (ophthalmic) and societal cost perspective reference case, cost-utility analyses comparing bevacizumab, ranibizumab, and aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD). DESIGN: Cost-utility analysis. METHODS: The authors performed 11-year and 2-year ophthalmic and societal cost perspective, cost-utility analyses comparing bevacizumab, ranibizumab, and aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD). We employed patient utilities, bilateral outcomes, 2018 U.S. dollars, vision-related mortality, a Medicare fee schedule, and CATT (Comparison of Age-Related Macular Degeneration Treatments) study and VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) trial. Cochrane data were also used. SETTING: Center for Value-Based Medicine. Patient/study population: patients with NVAMD. INTERVENTION: Cost-utility analyses using published data. Data-modeled 10-year vision outcomes were modeled forward to year 11. MAIN OUTCOME MEASUREMENT: These included cost-utility ratios (CURs), costs, and quality-adjusted life-years (QALYs) gained. $100,00/QALY was considered the US cost-effectiveness upper limit. RESULTS: Bevacizumab and ranibizumab each conferred an 11-year, 1.339 QALY gain versus observation. Aflibercept conferred a 1.380 QALY gain. Aflibercept conferred greater QALY gain for less cost than ranibizumab but was not cost-effective compared to bevacizumab ($1,151,451/QALY incremental CUR). The average ophthalmic cost perspective CUR for bevacizumab was $11,033/QALY, $79,600/QALY for ranibizumab, and $44,801/QALY for aflibercept. Eleven-year therapies saved a 1.0 year-of-life loss without treatment from the 11.0-year life expectancy. Early treatment was 138%-149% more cost-effective than late treatment. Two-year therapy prevented a 1-month-of-life loss, and revealed bevacizumab, ranibizumab, and aflibercept conferred 0.141, 0.141, and 0.164 QALY gains, respectively, with corresponding average CURs of $40,371/QALY, $335,726/QALY, and $168,006/QALY, respectively. CONCLUSIONS: From an ophthalmic (medical) cost perspective, bevacizumab, ranibizumab, and aflibercept NVAMD monotherapies were all cost-effective over 11 years, with bevacizumab 6.21× more cost-effective than ranibizumab and 3.06× more cost-effective than aflibercept. Two-year modeling revealed bevacizumab was cost-effective, whereas ranibizumab and aflibercept were not. Early treatment was critical for obtaining optimal vision and cost-effectiveness, as is long-term follow-up and adherence to treatment.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Brown GC, Brown MM, Rapuano S, et al. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2020. PMID: 32565050. doi:10.1016/j.ajo.2020.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。